Key facts
- It has raised $8.7M; the latest was Seed Round ($8.2M) in Jan 2026.
- Notable investors include StartX (US), Tesi, BioTools Innovator, Balnord, Inventure — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Avenue Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Avenue Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Avenue Biosciences
Developer of a protein manufacturing technology designed to accelerate the development of life-saving therapies. The company offers a platform that features high-throughput analysis of natural and synthetic signal peptides, machine learning algorithms for optimizing protein expression, compatibility with various mammalian protein production systems, enabling biotechnology and pharmaceutical companies to accelerate drug development timelines, reduce production costs, and advance the discovery of protein biologics and biosimilars.
- Sector
- Healthcare
- HQ
- Helsinki, Finland
- Employees
- 12
- Website
- avenuebiosciences.com/
- Ownership
- Privately Held (backing)
Avenue Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Avenue Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Avenue Biosciences in its N-PORT filings yet. We sweep new filings monthly.